Clinical Trials Report. The APPROVe Study: What We Should Learn from the VIOXX Withdrawal
Overview
Overview
Journal
Curr Hypertens Rep
Specialty
Cardiology & Vascular Diseases
Date
2005 Feb 3
PMID
15683585
Citations
1
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Perioperative pain management.
Pyati S, Gan T CNS Drugs. 2007; 21(3):185-211.
PMID: 17338592 DOI: 10.2165/00023210-200721030-00002.
References
1.
Farkouh M, Kirshner H, Harrington R, Ruland S, Verheugt F, Schnitzer T
. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004; 364(9435):675-84.
DOI: 10.1016/S0140-6736(04)16894-3.
View
2.
Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G
. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol. 2004; 68(2):341-50.
DOI: 10.1016/j.bcp.2004.03.029.
View
3.
Hermann M, Camici G, Fratton A, Hurlimann D, Tanner F, Hellermann J
. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation. 2003; 108(19):2308-11.
DOI: 10.1161/01.CIR.0000101683.30157.0B.
View
4.
Mamdani M, Juurlink D, Lee D, Rochon P, Kopp A, Naglie G
. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004; 363(9423):1751-6.
DOI: 10.1016/S0140-6736(04)16299-5.
View
5.
Solomon D, Schneeweiss S, Glynn R, Kiyota Y, Levin R, Mogun H
. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004; 109(17):2068-73.
DOI: 10.1161/01.CIR.0000127578.21885.3E.
View